News and Trends 8 Jul 2022 Biosyntia closes a €11.5M round to launch world’s first bio-based vitamin B7 A bio-based vitamin B7 is the first product to be commercialized as biotech company, Biosyntia, secures funding from a strong syndicate of capital investors. Biosyntia, manufactures sustainable and natural ingredients using precision fermentation and has a strong pipeline of active ingredients for use in beauty and nutrition products such as vitamins and antioxidants. A funding […] July 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 Biotech food colorant startup Phytolon seals $14.5M in funding Phytolon, a developer of fermentation-based natural food colors, has secured $14.5 million in funding, led by DSM Venturing, to further progress its technology towards commercialization. Other participation came from Cibus Fund, Ginkgo Bioworks (in-kind investment in the form of Foundry services) and The Trendlines Agrifood Fund. Participation in the series A funding also includes some […] July 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 8 Jul 2022Beyond Biotech podcast 4: CorePath, Rensselaer, Versameb This week’s guests are: Helen Zha, assistant professor of chemical and biological engineering and a member of the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic Institute; Versameb CEO Klaas Zuideveld; and Aamir Ehsan, CEO and medical director of CorePath and Celina Villa, medical director of Biopharma Division. Versameb gives presentation during World […] July 8, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 World’s first research project for an early detection, multi-cancer screening test launched in Singapore A project for the discovery and validation of new combinations of biomarkers that can detect multi-cancer early has been launched in Singapore. Biotechnology company, MiRXES Ptr Ltd, announced this week the signing of a memorandum of understanding signaling the launch of Project CADENCE (Cancer Detected Early caN be CurEd). It is the world’s first large-scale […] July 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2022 Treatments set to improve for lethal lung disease and ulcers following drug synergy data revelation New data has been published today (July 7) evidencing findings that could lead to better treatment for people with lethal lung infections and infected diabetic foot ulcers caused by antimicrobial resistant (AMR) bacteria. Clinical stage biotechnology company, Destiny Pharma plc., focused on the development of novel products to prevent life-threatening infections, revealed the publication of […] July 7, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2022 French Juvisé buys gastro product in €400M finance deal French pharmaceutical company, Juvisé has just bought worldwide commercial rights to Pylera from US biopharmaceutical company Abbvie. Juvisé negotiated financing of €400 million ($408 million) with Société Générale as part of the deal and also the refinancing of its existing debt. Pylera is an antimicrobial tri-therapy that helps gastro-intestinal Helicobacter pylori infections. Lazard and Latham […] July 7, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2022 Vaccizone chooses partner to fast-track development of COVID-19 vaccine A vaccine development company has chosen a partner to fast-track the development of its SARS-CoV-2 product for European clinical trials. Vaccizone has chosen viral vector contract development and manufacturing company (CDMO) antigen delivery technology Exothera S.A to accelerate the vaccine. Vaccizone is the inventor of the ASC Technology, a first-in-class antigen delivery platform for generating […] July 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2022 Finnish and US companies form exclusive agreement for development of sustained release drug A sustained release drug that can help people with age-related macular degeneration (AMD) has been given a global license agreement. DelSiTech and Iveric Bio have announced the agreement so Iveric Bio can develop and commercialize new formulations of drug Zimura (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion […] July 6, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2022 Exyte Builds mRNA Competence Center for WACKER in Germany A messenger ribonucleic acid (mRNA) competence center is being built at the Halle Biotech site of German company Wacker Chemie AG (WACKER). Exyte GmbH is a global design, engineering company that delivers facilities for high-tech industries and is in charge of the site at WACKER. The project is making a considerable contribution towards strengthening the […] July 6, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2022 New discovery center to house scientists opens in India A discovery services center spanning 100,000 sq ft has been set up in Pune, India, to house a talent of chemists, biologists and formulation scientists. TCG Lifesciences Pvt. Limited (TCGLS), in charge of facilitating the center, is a global contract research and contract development and manufacturing company delivering research and development services in the pharmaceutical […] July 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Poxel publishes ALD studies Two preclinical articles have been published in different journals for treatments being developed by French biopharmaceutical company, Poxel. Poxel develops treatments for chronic, serious diseases with metabolic pathophysiology including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The articles have been about genetic disease X-Linked Adrenoleukodystrophy (ALD) and molecules PXL065 and PXL770. These molecules have separate […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Destiny Pharma announces start of new oral mucositis research program Oral mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2 million cancer patients every year. Destiny Pharma plc, a clinical-stage biotech company focused on the development of novel medicines that can prevent life-threatening infections, has started a new research program on the condition. The research study will be […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email